Louis A. Cona, MD

Our Medical Director, Louis A. Cona, MD, is a pioneer in regenerative cell therapy, providing
the first stem cell treatments in the Cayman Islands more than a decade ago. He continues
to research alternative therapies for various medical conditions, and with IRB-approved
clinical trials, has treated hundreds of  patients for Multiple Sclerosis (MS), Chronic Low
Grade Inflammation (which is part of the overall Aging Process), and many other
degenerative conditions.

Louis A. Cona, MD is a recognized member of the British Medical Association, the General Medical Council (UK), the Caribbean College of Family Physicians, and the American Academy of Family Physicians.

He is also certified by the American Academy of Aesthetic Practitioners and is a member of the World Academy of Anti-Aging Medicine (WAAAM). He is an associate professor at St. Matthews School of Medicine, Deputy Chair of the Health Practice Commission Cayman Islands Government, past chairman of Medical + Dental Council of the Cayman Islands, Medical Director of the Strand Medical Centre, past president of Cayman Islands Medical & Dental Society.

Quick Facts

Supervising Physician – Dr. Cona is present for all infusions that occur within the facility. Patients will be able to meet & discuss the treatment protocol with him upon arrival in the Cayman Islands.

Over 30 years experience – Originally from New York.  USA, Dr. Cona completed his MD programme in Medicine and Surgery at the University of Turin in Italy.  He has practiced medicine internationally and has been in the Cayman Islands practicing for over 25 years.

American Academy of Anti-Aging Medicine – Dr. Cona is an active member of the A4M, a society of anti-aging and regenerative medicine physicians, healthcare practitioners and scientists dedicated to enhancing the quality and extending the length of the human lifespan.

World Society of Interdisciplinary Anti-Aging Medicine – Dr. Cona is entitled, as a member, to represent the WOSIAM in his country with all the prerogatives such as defined in the social aim.

Preliminary Efficacy Data

We are currently still collecting long-term data and do not have any published results to share specifically related to our IRB-approved clinical trials. (Trial HPC/CTR/003).

However, preliminary data that has been collected over the past 5 years has been exciting.

Patient reported results have since shown that ~85% of our total patient population have noted a sustained improvement in their condition within 3 months of treatment.

Average Improvements 3 Months Post-treatment

Stamina – 75% Improvement

Libido – 53.75% Improvement

Energy Levels – 51.40% Improvement

Balance – 43.97% Improvement

Coordination – 28% Improvement

Strength – 23.19% Improvement

Vision – 21% Improvement

Memory – 19.84% Improvement

Concentration – 44% Improvement

Quality of Sleep – 12.5% Improvement

Expected Improvement Timeline

Study participants may produce measurable results within 3-6 months following their infusion. This is indicated by a marked reduction in levels of systemic inflammation and changes in general vitality as measure by our follow-up questionnaire.

However, it is common for patients to report improvements in their quality of life and a lessening of their symptoms within the first few weeks following their infusion. However, every patient is unique and may respond to treatment differently. View all patient testimonials here.